Safety and efficacy of cilostazol in the management of intermittent claudication Article

Full Text via DOI: 10.2147/VHRM.S3160 PMID: 19337533 Web of Science: 000210386300006

Cited authors

  • Chi, Yung-Wei; Lavie, Carl J.; Milani, Richard V.; White, Christopher J.


  • Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

Publication date

  • 2008

Published in

International Standard Serial Number (ISSN)

  • 1176-6344

Start page

  • 1197

End page

  • 1203


  • 4


  • 6